Neoadjuvant chemotherapy in patients with advanced endometrial cancer. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-12

AUTHORS

Olivia R Khouri, Melissa K Frey, Fernanda Musa, Franco Muggia, Jessica Lee, Leslie Boyd, John P Curtin, Bhavana Pothuri

ABSTRACT

OBJECTIVES: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a treatment strategy for ovarian cancer patients with unresectable disease or poor performance status (PS). This strategy has been used in the treatment of advanced endometrial cancer and a survival benefit has been shown in patients who are subsequently able to undergo interval cytoreduction. This study sought to review our single institution experience with NACT for advanced endometrial cancer. METHODS: We conducted a retrospective review of all patients who received NACT for advanced endometrial cancer at two institutions in New York City between 2002 and 2016. RESULTS: We identified 39 patients (median age 61, range 35-89). The histologic subtype distribution was: serous (44%), endometrioid (28%), carcinosarcoma (10%), clear cell (8%), mixed (8%), neuroendocrine (3%). Contraindications to primary surgery included: unresectable disease (72%), poor PS (15%), unresectable disease and poor PS (13%). Twenty-three patients (59%) did not undergo IDS due to: progression of disease (70%), medical ineligibility (4%), unresectable disease (17%), lost to follow-up (4%), death (4%). Sixteen patients (41%) underwent IDS, 81% had an optimal cytoreduction. Disease status at NACT completion was: partial response (56%), stable disease (3%) and progression of disease (41%). There were no complete responses. Patients who responded to NACT had a significantly longer overall survival than those who did not (15 vs. 5 months. P = 0.015). IDS was also associated with an improvement in overall survival versus no surgery (16 vs. 6 months, P = 0.04). CONCLUSIONS: Unlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03838-x

DOI

http://dx.doi.org/10.1007/s00280-019-03838-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113380452

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30980132


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, School of Medicine, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khouri", 
        "givenName": "Olivia R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cornell University", 
          "id": "https://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "New York Presbyterian - Weill Cornell Medical College, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Frey", 
        "givenName": "Melissa K", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Swedish Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.281044.b", 
          "name": [
            "Pacific Gynecology Specialists, Swedish Cancer Institute, Seattle, WA, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Musa", 
        "givenName": "Fernanda", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, School of Medicine, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Muggia", 
        "givenName": "Franco", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "University of Texas, Southwestern, Dallas, TX, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jessica", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, School of Medicine, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boyd", 
        "givenName": "Leslie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, School of Medicine, New York, NY, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curtin", 
        "givenName": "John P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University, School of Medicine, New York, NY, USA. bhavana.pothuri@nyumc.org."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pothuri", 
        "givenName": "Bhavana", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1006/gyno.1998.5213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002062605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2014.12.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013879175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0090-8258(90)90361-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023400222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024868939", 
          "https://doi.org/10.1038/sj.bjc.6605157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)67063-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029890761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)67063-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029890761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2016.05.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030933544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2016.05.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030933544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2008.11.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040296744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)62223-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049767484"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-12", 
    "datePublishedReg": "2019-04-12", 
    "description": "OBJECTIVES: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a treatment strategy for ovarian cancer patients with unresectable disease or poor performance status (PS). This strategy has been used in the treatment of advanced endometrial cancer and a survival benefit has been shown in patients who are subsequently able to undergo interval cytoreduction. This study sought to review our single institution experience with NACT for advanced endometrial cancer.\nMETHODS: We conducted a retrospective review of all patients who received NACT for advanced endometrial cancer at two institutions in New York City between 2002 and 2016.\nRESULTS: We identified 39 patients (median age 61, range 35-89). The histologic subtype distribution was: serous (44%), endometrioid (28%), carcinosarcoma (10%), clear cell (8%), mixed (8%), neuroendocrine (3%). Contraindications to primary surgery included: unresectable disease (72%), poor PS (15%), unresectable disease and poor PS (13%). Twenty-three patients (59%) did not undergo IDS due to: progression of disease (70%), medical ineligibility (4%), unresectable disease (17%), lost to follow-up (4%), death (4%). Sixteen patients (41%) underwent IDS, 81% had an optimal cytoreduction. Disease status at NACT completion was: partial response (56%), stable disease (3%) and progression of disease (41%). There were no complete responses. Patients who responded to NACT had a significantly longer overall survival than those who did not (15 vs. 5\u00a0months. P\u2009=\u20090.015). IDS was also associated with an improvement in overall survival versus no surgery (16 vs. 6\u00a0months, P\u2009=\u20090.04).\nCONCLUSIONS: Unlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-019-03838-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "Neoadjuvant chemotherapy in patients with advanced endometrial cancer.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03838-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113380452"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30980132"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03838-x", 
      "https://app.dimensions.ai/details/publication/pub.1113380452"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106822_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00280-019-03838-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03838-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03838-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03838-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03838-x'


 

This table displays all metadata directly associated to this object as RDF triples.

137 TRIPLES      20 PREDICATES      33 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03838-x schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Neab616213fba48f99919cdad40dfa7ab
4 schema:citation sg:pub.10.1038/sj.bjc.6605157
5 https://doi.org/10.1006/gyno.1998.5213
6 https://doi.org/10.1016/0090-8258(90)90361-n
7 https://doi.org/10.1016/j.ejca.2008.10.026
8 https://doi.org/10.1016/j.ygyno.2008.11.014
9 https://doi.org/10.1016/j.ygyno.2014.12.004
10 https://doi.org/10.1016/j.ygyno.2016.05.022
11 https://doi.org/10.1016/s0140-6736(05)67063-8
12 https://doi.org/10.1016/s0140-6736(14)62223-6
13 schema:datePublished 2019-04-12
14 schema:datePublishedReg 2019-04-12
15 schema:description OBJECTIVES: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a treatment strategy for ovarian cancer patients with unresectable disease or poor performance status (PS). This strategy has been used in the treatment of advanced endometrial cancer and a survival benefit has been shown in patients who are subsequently able to undergo interval cytoreduction. This study sought to review our single institution experience with NACT for advanced endometrial cancer. METHODS: We conducted a retrospective review of all patients who received NACT for advanced endometrial cancer at two institutions in New York City between 2002 and 2016. RESULTS: We identified 39 patients (median age 61, range 35-89). The histologic subtype distribution was: serous (44%), endometrioid (28%), carcinosarcoma (10%), clear cell (8%), mixed (8%), neuroendocrine (3%). Contraindications to primary surgery included: unresectable disease (72%), poor PS (15%), unresectable disease and poor PS (13%). Twenty-three patients (59%) did not undergo IDS due to: progression of disease (70%), medical ineligibility (4%), unresectable disease (17%), lost to follow-up (4%), death (4%). Sixteen patients (41%) underwent IDS, 81% had an optimal cytoreduction. Disease status at NACT completion was: partial response (56%), stable disease (3%) and progression of disease (41%). There were no complete responses. Patients who responded to NACT had a significantly longer overall survival than those who did not (15 vs. 5 months. P = 0.015). IDS was also associated with an improvement in overall survival versus no surgery (16 vs. 6 months, P = 0.04). CONCLUSIONS: Unlike ovarian cancer, less than half of the patients undergoing NACT for endometrial cancer underwent IDS, none had a complete response, and 41% had disease progression during NACT. However, endometrial cancer patients who underwent IDS had a high rate of optimal cytoreduction. Both response to NACT and IDS were associated with improved survival.
16 schema:genre research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf sg:journal.1088364
20 schema:name Neoadjuvant chemotherapy in patients with advanced endometrial cancer.
21 schema:productId N6af715e8723f44d4ba5b414ef5b6f2a0
22 Nb10a6858ba8845cfbfea2a83d5e8e1f1
23 Nd3bc3d3656fa47db9b5f32b57cf46ae0
24 Nfdefb62f7a084b90a8f8884cd712e564
25 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113380452
26 https://doi.org/10.1007/s00280-019-03838-x
27 schema:sdDatePublished 2019-04-16T06:23
28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
29 schema:sdPublisher N7b3af4b7d1714b168dfd73c0f39d529f
30 schema:url http://link.springer.com/10.1007/s00280-019-03838-x
31 sgo:license sg:explorer/license/
32 sgo:sdDataset articles
33 rdf:type schema:ScholarlyArticle
34 N2d03fc8cda2a4202bbf34be5efca2941 schema:affiliation https://www.grid.ac/institutes/grid.267313.2
35 schema:familyName Lee
36 schema:givenName Jessica
37 rdf:type schema:Person
38 N2e4c760b9c9849a296bf28785b9375f9 rdf:first N2d03fc8cda2a4202bbf34be5efca2941
39 rdf:rest Nfcda3774381343c6b4eb86be17aa5816
40 N5b7876e5ae2a4d55bf86d167f046eeec rdf:first N91cc48d8687f440ebfce735f4e5c05af
41 rdf:rest Nb5f6c2483b08457cb5527df1d6fdd788
42 N673bc22f1447462a8b5a5be643563c09 schema:affiliation https://www.grid.ac/institutes/grid.281044.b
43 schema:familyName Musa
44 schema:givenName Fernanda
45 rdf:type schema:Person
46 N6af715e8723f44d4ba5b414ef5b6f2a0 schema:name pubmed_id
47 schema:value 30980132
48 rdf:type schema:PropertyValue
49 N7040b0aa368b423b88d1a73deed97e8b schema:affiliation https://www.grid.ac/institutes/grid.137628.9
50 schema:familyName Pothuri
51 schema:givenName Bhavana
52 rdf:type schema:Person
53 N7b3af4b7d1714b168dfd73c0f39d529f schema:name Springer Nature - SN SciGraph project
54 rdf:type schema:Organization
55 N8c02469d055d45d7a24ab1b10df52820 schema:affiliation https://www.grid.ac/institutes/grid.137628.9
56 schema:familyName Khouri
57 schema:givenName Olivia R
58 rdf:type schema:Person
59 N8dcfbdfe328e408b8cc7a1eb756be661 rdf:first Na4cd3c5dc0bb40c88b3a3c3c4a2fcb72
60 rdf:rest Nc975ecd55cea41089980bfe4b81918b4
61 N91cc48d8687f440ebfce735f4e5c05af schema:affiliation https://www.grid.ac/institutes/grid.137628.9
62 schema:familyName Curtin
63 schema:givenName John P
64 rdf:type schema:Person
65 N97aba43024df41a3b3a821bf66bf5629 rdf:first Nf509e9a688de445abcdf98b6aa571420
66 rdf:rest N2e4c760b9c9849a296bf28785b9375f9
67 Na4cd3c5dc0bb40c88b3a3c3c4a2fcb72 schema:affiliation https://www.grid.ac/institutes/grid.5386.8
68 schema:familyName Frey
69 schema:givenName Melissa K
70 rdf:type schema:Person
71 Nb10a6858ba8845cfbfea2a83d5e8e1f1 schema:name doi
72 schema:value 10.1007/s00280-019-03838-x
73 rdf:type schema:PropertyValue
74 Nb5f6c2483b08457cb5527df1d6fdd788 rdf:first N7040b0aa368b423b88d1a73deed97e8b
75 rdf:rest rdf:nil
76 Nc975ecd55cea41089980bfe4b81918b4 rdf:first N673bc22f1447462a8b5a5be643563c09
77 rdf:rest N97aba43024df41a3b3a821bf66bf5629
78 Nd3bc3d3656fa47db9b5f32b57cf46ae0 schema:name nlm_unique_id
79 schema:value 7806519
80 rdf:type schema:PropertyValue
81 Nd8be599439d3436296d6660dc7d7348d schema:affiliation https://www.grid.ac/institutes/grid.137628.9
82 schema:familyName Boyd
83 schema:givenName Leslie
84 rdf:type schema:Person
85 Neab616213fba48f99919cdad40dfa7ab rdf:first N8c02469d055d45d7a24ab1b10df52820
86 rdf:rest N8dcfbdfe328e408b8cc7a1eb756be661
87 Nf509e9a688de445abcdf98b6aa571420 schema:affiliation https://www.grid.ac/institutes/grid.137628.9
88 schema:familyName Muggia
89 schema:givenName Franco
90 rdf:type schema:Person
91 Nfcda3774381343c6b4eb86be17aa5816 rdf:first Nd8be599439d3436296d6660dc7d7348d
92 rdf:rest N5b7876e5ae2a4d55bf86d167f046eeec
93 Nfdefb62f7a084b90a8f8884cd712e564 schema:name dimensions_id
94 schema:value pub.1113380452
95 rdf:type schema:PropertyValue
96 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
97 schema:name Medical and Health Sciences
98 rdf:type schema:DefinedTerm
99 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
100 schema:name Oncology and Carcinogenesis
101 rdf:type schema:DefinedTerm
102 sg:journal.1088364 schema:issn 0344-5704
103 1432-0843
104 schema:name Cancer Chemotherapy and Pharmacology
105 rdf:type schema:Periodical
106 sg:pub.10.1038/sj.bjc.6605157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024868939
107 https://doi.org/10.1038/sj.bjc.6605157
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1006/gyno.1998.5213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002062605
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/0090-8258(90)90361-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1023400222
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1016/j.ygyno.2008.11.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040296744
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1016/j.ygyno.2014.12.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013879175
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1016/j.ygyno.2016.05.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030933544
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/s0140-6736(05)67063-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029890761
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/s0140-6736(14)62223-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049767484
124 rdf:type schema:CreativeWork
125 https://www.grid.ac/institutes/grid.137628.9 schema:alternateName New York University
126 schema:name New York University, School of Medicine, New York, NY, USA.
127 New York University, School of Medicine, New York, NY, USA. bhavana.pothuri@nyumc.org.
128 rdf:type schema:Organization
129 https://www.grid.ac/institutes/grid.267313.2 schema:alternateName The University of Texas Southwestern Medical Center
130 schema:name University of Texas, Southwestern, Dallas, TX, USA.
131 rdf:type schema:Organization
132 https://www.grid.ac/institutes/grid.281044.b schema:alternateName Swedish Medical Center
133 schema:name Pacific Gynecology Specialists, Swedish Cancer Institute, Seattle, WA, USA.
134 rdf:type schema:Organization
135 https://www.grid.ac/institutes/grid.5386.8 schema:alternateName Cornell University
136 schema:name New York Presbyterian - Weill Cornell Medical College, New York, NY, USA.
137 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...